Switch to:
Also traded in: Austria, Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.72
ILMN's Cash-to-Debt is ranked higher than
62% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. ILMN: 1.72 )
Ranked among companies with meaningful Cash-to-Debt only.
ILMN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: 1.73 Max: 16544
Current: 1.72
0.69
16544
Equity-to-Asset 0.52
ILMN's Equity-to-Asset is ranked lower than
51% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ILMN: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
ILMN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.55 Max: 0.94
Current: 0.52
0.36
0.94
Debt-to-Equity 0.56
ILMN's Debt-to-Equity is ranked higher than
51% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. ILMN: 0.56 )
Ranked among companies with meaningful Debt-to-Equity only.
ILMN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.47 Max: 1.5
Current: 0.56
0
1.5
Debt-to-EBITDA 1.75
ILMN's Debt-to-EBITDA is ranked higher than
71% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. ILMN: 1.75 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ILMN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.96  Med: 1.93 Max: 3.41
Current: 1.75
0.96
3.41
Interest Coverage 19.08
ILMN's Interest Coverage is ranked lower than
54% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. ILMN: 19.08 )
Ranked among companies with meaningful Interest Coverage only.
ILMN' s Interest Coverage Range Over the Past 10 Years
Min: 4.92  Med: 7.73 Max: 19.08
Current: 19.08
4.92
19.08
Piotroski F-Score: 6
Altman Z-Score: 10.91
Beneish M-Score: -2.79
WACC vs ROIC
15.06%
31.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 28.25
ILMN's Operating Margin % is ranked higher than
89% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. ILMN: 28.25 )
Ranked among companies with meaningful Operating Margin % only.
ILMN' s Operating Margin % Range Over the Past 10 Years
Min: 17.88  Med: 22.42 Max: 28.47
Current: 28.25
17.88
28.47
Net Margin % 21.10
ILMN's Net Margin % is ranked higher than
95% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. ILMN: 21.10 )
Ranked among companies with meaningful Net Margin % only.
ILMN' s Net Margin % Range Over the Past 10 Years
Min: 6.88  Med: 13.5 Max: 26.38
Current: 21.1
6.88
26.38
ROE % 22.25
ILMN's ROE % is ranked higher than
95% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. ILMN: 22.25 )
Ranked among companies with meaningful ROE % only.
ILMN' s ROE % Range Over the Past 10 Years
Min: 6.51  Med: 12.38 Max: 29.32
Current: 22.25
6.51
29.32
ROA % 12.02
ILMN's ROA % is ranked higher than
92% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. ILMN: 12.02 )
Ranked among companies with meaningful ROA % only.
ILMN' s ROA % Range Over the Past 10 Years
Min: 3.41  Med: 7 Max: 15.22
Current: 12.02
3.41
15.22
ROC (Joel Greenblatt) % 77.81
ILMN's ROC (Joel Greenblatt) % is ranked higher than
98% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. ILMN: 77.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ILMN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 56.69  Med: 78.88 Max: 133.65
Current: 77.81
56.69
133.65
3-Year Revenue Growth Rate 14.20
ILMN's 3-Year Revenue Growth Rate is ranked higher than
80% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ILMN: 14.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ILMN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1  Med: 21.95 Max: 156.2
Current: 14.2
-1
156.2
3-Year EBITDA Growth Rate 27.30
ILMN's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. ILMN: 27.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ILMN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 27.4 Max: 119.6
Current: 27.3
0
119.6
3-Year EPS without NRI Growth Rate 27.60
ILMN's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. ILMN: 27.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ILMN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26.95 Max: 56.4
Current: 27.6
0
56.4
GuruFocus has detected 1 Warning Sign with Illumina Inc ILMN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ILMN's 30-Y Financials

Financials (Next Earnings Date: 2019-01-31 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ILMN Guru Trades in Q3 2017

Ray Dalio 63,012 sh (+236.55%)
First Eagle Investment 400 sh (unchged)
Caxton Associates Sold Out
Ron Baron 444,335 sh (-0.94%)
Steven Cohen 62,800 sh (-1.10%)
Frank Sands 4,926,817 sh (-5.58%)
PRIMECAP Management 1,903,230 sh (-6.49%)
Vanguard Health Care Fund 1,920,681 sh (-27.97%)
Jim Simons 133,218 sh (-50.83%)
Spiros Segalas 1,523,457 sh (-20.79%)
» More
Q4 2017

ILMN Guru Trades in Q4 2017

Tom Gayner 1,000 sh (New)
Pioneer Investments 35,948 sh (New)
Joel Greenblatt 2,009 sh (New)
Steven Cohen 87,600 sh (+39.49%)
First Eagle Investment 400 sh (unchged)
Ray Dalio Sold Out
PRIMECAP Management 1,887,360 sh (-0.83%)
Frank Sands 4,752,498 sh (-3.54%)
Ron Baron 414,734 sh (-6.66%)
Vanguard Health Care Fund 1,557,088 sh (-18.93%)
Jim Simons 43,818 sh (-67.11%)
Spiros Segalas 1,410,258 sh (-7.43%)
» More
Q1 2018

ILMN Guru Trades in Q1 2018

Mario Gabelli 4,770 sh (New)
Pioneer Investments 79,607 sh (+121.45%)
Ron Baron 420,580 sh (+1.41%)
Spiros Segalas 1,508,475 sh (+6.96%)
Tom Gayner 1,000 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
First Eagle Investment Sold Out
PRIMECAP Management 1,873,520 sh (-0.73%)
Frank Sands 4,463,446 sh (-6.08%)
Vanguard Health Care Fund 1,357,888 sh (-12.79%)
Jim Simons 18,218 sh (-58.42%)
» More
Q2 2018

ILMN Guru Trades in Q2 2018

Andreas Halvorsen 500,763 sh (New)
Paul Tudor Jones 16,039 sh (New)
Steven Cohen 85,900 sh (New)
Jim Simons 63,618 sh (+249.20%)
Pioneer Investments 132,350 sh (+66.25%)
Mario Gabelli 6,700 sh (+40.46%)
Ron Baron 429,790 sh (+2.19%)
Tom Gayner 1,000 sh (unchged)
Frank Sands 4,270,391 sh (-4.33%)
Vanguard Health Care Fund 1,214,488 sh (-10.56%)
PRIMECAP Management 1,126,843 sh (-39.85%)
Spiros Segalas 1,483,925 sh (-1.63%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ILMN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:BAX, XPAR:EI, TSE:4543, OCSE:COLO B, NYSE:WAT, NYSE:MTD, NYSE:RMD, TSE:7733, NAS:XRAY, NYSE:COO, XSWX:STMN, NAS:HOLX, NYSE:BDX, NYSE:STE, SZSE:002294, NYSE:WST, NYSE:HRC, NAS:ICUI, NAS:PODD, NYSE:CMD » details
Traded in other countries:ILMN.Austria, ILU.Germany, ILMN.Mexico,
Headquarter Location:USA
Illumina Inc engages in life science tools and machines for analyzing genetic material. The company primarily engages in microarray and genome sequencing machines and disposables. It also provides sequencing services through its products.

Illumina Inc is a major player in life science tools for analyzing genetic material. Revenue from microarray and genome sequencing machines and disposables make up most of the company's revenue, but approximately 10% of the company's sales come from sequencing services. Essentially all of Illumina's growth stems from the company's genome sequencing products, which include the company's high-throughput NovaSeq and HiSeq instruments in addition to its benchtop NextSeq, MiSeq, and MiniSeq, and iSeq product lines.

Guru Investment Theses on Illumina Inc

Baron Opportunity Fund Comments on Illumina - Feb 21, 2017

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell in the fourth quarter after reporting disappointing third quarter financial results. The third quarter shortfall was driven by weak high-throughput instrument sales. However, at the J.P. Morgan Healthcare Conference in January, Illumina announced an exciting new high-throughput sequencing platform, called NovaSeq, which has the potential in future years to deliver the world’s first $100 full human genome. We continue to believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment. (Neal Kaufman)



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds' Fifth Avenue Growth Fund Comments on Illumina - Feb 13, 2017

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell almost 30% after reporting disappointing third quarter financial results. The shortfall was caused primarily by weak high-throughput instrument sales in North America and general weakness in Europe. Illumina’s growth is very much driven by new product introductions, and in 2016 sales suffered as the high- throughput instrument line reached the end of its life cycle. In early 2017, Illumina launched a new high- throughput sequencing platform that should re-accelerate growth. In addition, Grail, the start-up funded by Illumina which is developing a blood-based cancer screening test, announced it received capital commitments of $1 billion and would become one of Illumina’s largest customers over time. We continue to believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Asset Fund Comments on Illumina Inc. - Jan 30, 2017

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell after reporting disappointing financial results. The quarterly shortfall was driven by weak sales of its high-throughput instruments. We reduced the size of our position but continue to own the stock because we believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment. We are encouraged that the shares have had a meaningful recovery in early January, as the company provided encouraging earnings guidance for 2017 and launched a powerful, new DNA sequencing platform.



From Barron Asset Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Illumina Inc

Illumina’s Growth Shows No Signs of Slowing Down Illumina's recent acquisition of Pacific Biosciences of California strongly strengthens its product offering and ensures growth for years to come
Earlier in the month, Illumina (ILMN) made an aggressive and surprising move: acquiring Pacific Biosciences (PACB), one of its direct competitors, for $1.2 billion. To date, this is the largest acquisition that Illumina has ever made. Read more...
Helix Launches the New DNA Discovery Kit
Inscripta Announces Strategic Acquisition of Solana Biosciences
US Stocks With Positive Direction Tuesday Illumina rises on earnings
U.S. stock markets were higher in morning trading Tuesday, ahead of a positive report that the consumer confidence index rose to 127.4 in July from a revised 127.1 in the previous month. Read more...
Update: Lawsuit for Investors in NASDAQ: ILMN shares against Illumina, Inc. announced by Shareholders Foundation
ILLUMINA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Illumina, Inc. - ILMN
New Research Coverage Highlights Illumina, Vectren, Chemours, Fastenal, Norwegian Cruise Line, and Globalstar — Consolidated Revenues, Company Growth, and Expectations for 2018
Luna DNA Announces Dawn Barry, former Illumina VP, as President
First Genomic Platform Powered by the Blockchain Raises $2 Million in Funding; Backed by Illumina Veterans
Market Trends Toward New Normal in Illumina, Vectren, Chemours, Fastenal, Norwegian Cruise Line, and Globalstar — Emerging Consolidated Expectations, Analyst Ratings

Ratios

vs
industry
vs
history
PE Ratio 69.25
ILMN's PE Ratio is ranked lower than
90% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. ILMN: 69.25 )
Ranked among companies with meaningful PE Ratio only.
ILMN' s PE Ratio Range Over the Past 10 Years
Min: 32.28  Med: 70.64 Max: 302.86
Current: 69.25
32.28
302.86
Forward PE Ratio 50.25
ILMN's Forward PE Ratio is ranked lower than
95% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ILMN: 50.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 69.25
ILMN's PE Ratio without NRI is ranked lower than
88% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. ILMN: 69.25 )
Ranked among companies with meaningful PE Ratio without NRI only.
ILMN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 32.28  Med: 70.64 Max: 302.86
Current: 69.25
32.28
302.86
Price-to-Owner-Earnings 63.20
ILMN's Price-to-Owner-Earnings is ranked lower than
63% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. ILMN: 63.20 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ILMN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.62  Med: 55.91 Max: 97.42
Current: 63.2
20.62
97.42
PB Ratio 13.43
ILMN's PB Ratio is ranked lower than
74% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. ILMN: 13.43 )
Ranked among companies with meaningful PB Ratio only.
ILMN' s PB Ratio Range Over the Past 10 Years
Min: 2.88  Med: 8.77 Max: 23.59
Current: 13.43
2.88
23.59
PS Ratio 14.63
ILMN's PS Ratio is ranked lower than
76% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. ILMN: 14.63 )
Ranked among companies with meaningful PS Ratio only.
ILMN' s PS Ratio Range Over the Past 10 Years
Min: 3.54  Med: 9.97 Max: 17.19
Current: 14.63
3.54
17.19
Price-to-Free-Cash-Flow 57.22
ILMN's Price-to-Free-Cash-Flow is ranked lower than
78% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. ILMN: 57.22 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ILMN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.31  Med: 45.59 Max: 127.5
Current: 57.22
13.31
127.5
Price-to-Operating-Cash-Flow 41.76
ILMN's Price-to-Operating-Cash-Flow is ranked lower than
79% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. ILMN: 41.76 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ILMN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.31  Med: 32.37 Max: 344.72
Current: 41.76
10.31
344.72
EV-to-EBIT 47.80
ILMN's EV-to-EBIT is ranked lower than
75% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. ILMN: 47.80 )
Ranked among companies with meaningful EV-to-EBIT only.
ILMN' s EV-to-EBIT Range Over the Past 10 Years
Min: 17  Med: 40.35 Max: 1825.9
Current: 47.8
17
1825.9
EV-to-EBITDA 40.66
ILMN's EV-to-EBITDA is ranked lower than
79% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. ILMN: 40.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
ILMN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.6  Med: 32.55 Max: 222.2
Current: 40.66
12.6
222.2
EV-to-Revenue 14.10
ILMN's EV-to-Revenue is ranked lower than
73% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. ILMN: 14.10 )
Ranked among companies with meaningful EV-to-Revenue only.
ILMN' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.8  Med: 9.8 Max: 17.4
Current: 14.1
2.8
17.4
PEG Ratio 2.38
ILMN's PEG Ratio is ranked higher than
60% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. ILMN: 2.38 )
Ranked among companies with meaningful PEG Ratio only.
ILMN' s PEG Ratio Range Over the Past 10 Years
Min: 0.67  Med: 1.83 Max: 13.16
Current: 2.38
0.67
13.16
Shiller PE Ratio 138.84
ILMN's Shiller PE Ratio is ranked lower than
99.99% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. ILMN: 138.84 )
Ranked among companies with meaningful Shiller PE Ratio only.
ILMN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 99.64  Med: 235.61 Max: 3600
Current: 138.84
99.64
3600
Current Ratio 2.49
ILMN's Current Ratio is ranked higher than
78% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. ILMN: 2.49 )
Ranked among companies with meaningful Current Ratio only.
ILMN' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 4.35 Max: 60.21
Current: 2.49
0.99
60.21
Quick Ratio 2.27
ILMN's Quick Ratio is ranked higher than
82% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ILMN: 2.27 )
Ranked among companies with meaningful Quick Ratio only.
ILMN' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 4.02 Max: 60.21
Current: 2.27
0.87
60.21
Days Inventory 128.75
ILMN's Days Inventory is ranked higher than
52% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. ILMN: 128.75 )
Ranked among companies with meaningful Days Inventory only.
ILMN' s Days Inventory Range Over the Past 10 Years
Min: 111.78  Med: 132.78 Max: 147.41
Current: 128.75
111.78
147.41
Days Sales Outstanding 48.75
ILMN's Days Sales Outstanding is ranked higher than
70% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. ILMN: 48.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
ILMN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.75  Med: 63.31 Max: 86.41
Current: 48.75
48.75
86.41
Days Payable 57.52
ILMN's Days Payable is ranked higher than
67% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. ILMN: 57.52 )
Ranked among companies with meaningful Days Payable only.
ILMN' s Days Payable Range Over the Past 10 Years
Min: 51.84  Med: 63.53 Max: 93.62
Current: 57.52
51.84
93.62

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.80
ILMN's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. ILMN: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ILMN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: -5.1 Max: -0.3
Current: -0.8
-13.6
-0.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 355.47
ILMN's Price-to-Net-Cash is ranked lower than
99.99% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.60 vs. ILMN: 355.47 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ILMN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.14  Med: 25.04 Max: 407.84
Current: 355.47
2.14
407.84
Price-to-Net-Current-Asset-Value 46.77
ILMN's Price-to-Net-Current-Asset-Value is ranked lower than
84% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.88 vs. ILMN: 46.77 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ILMN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.95  Med: 12.9 Max: 2050.89
Current: 46.77
1.95
2050.89
Price-to-Tangible-Book 18.99
ILMN's Price-to-Tangible-Book is ranked lower than
75% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. ILMN: 18.99 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ILMN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.17  Med: 8.51 Max: 461.34
Current: 18.99
1.17
461.34
Price-to-Intrinsic-Value-Projected-FCF 4.82
ILMN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
81% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ILMN: 4.82 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ILMN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.53  Med: 4.46 Max: 42.17
Current: 4.82
1.53
42.17
Price-to-Intrinsic-Value-DCF (Earnings Based) 6.47
ILMN's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
99.99% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. ILMN: 6.47 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ILMN' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 3.21  Med: 4.01 Max: 7.42
Current: 6.47
3.21
7.42
Price-to-Median-PS-Value 1.46
ILMN's Price-to-Median-PS-Value is ranked lower than
55% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ILMN: 1.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ILMN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.01 Max: 66.74
Current: 1.46
0.4
66.74
Price-to-Peter-Lynch-Fair-Value 2.77
ILMN's Price-to-Peter-Lynch-Fair-Value is ranked higher than
50% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. ILMN: 2.77 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ILMN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.37  Med: 2.56 Max: 9.54
Current: 2.77
1.37
9.54
Price-to-Graham-Number 7.64
ILMN's Price-to-Graham-Number is ranked lower than
99.99% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.98 vs. ILMN: 7.64 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ILMN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 3.52  Med: 6.68 Max: 49.18
Current: 7.64
3.52
49.18
Earnings Yield (Greenblatt) % 2.09
ILMN's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. ILMN: 2.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ILMN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 2.5 Max: 5.9
Current: 2.09
0.1
5.9
Forward Rate of Return (Yacktman) % 21.14
ILMN's Forward Rate of Return (Yacktman) % is ranked higher than
93% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. ILMN: 21.14 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ILMN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.5  Med: 21.1 Max: 23.3
Current: 21.14
-0.5
23.3

More Statistics

Revenue (TTM) (Mil) $3,242.00
EPS (TTM) $ 4.62
Beta2.04
Volatility29.99%
52-Week Range $205.41 - 372.61
Shares Outstanding (Mil)147.00

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 3,317 3,766 4,257 4,948
EBIT (Mil $) 943 1,106 1,303
EBITDA (Mil $) 1,107 1,297 1,493 1,702
EPS ($) 5.37 5.96 6.83 8.71
EPS without NRI ($) 5.37 5.96 6.83 8.71
EPS Growth Rate
(Future 3Y To 5Y Estimate)
21.26%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}